Search PubMed⌕ Search

Biomedical subjects

D Kapoor

Publications and source records attributed to D Kapoor.

40 records · Page 3Linked to original sources

Blood transfusion practices in India: results of a national survey.

BACKGROUND: Blood transfusion may lead to serious clinical consequences for the recipient, if the transfused blood is not safe. To assess the functioning of the blood banks in India, a nation-wide, questionnaire-based study was conducted between November 1995 and November 1996 under the auspices of the Indian Association for Study of the Liver. METHODS: Of 604 blood banks in 31 states and union territories to whom the questionnaires were sent, responses wereobtained from 78 (13%) blood banks in 17 (54.8%) states, providing information on 275,000 donors. RESULTS: A majority (58%) of donors in these blood banks were replacement donors, followed by voluntary (39.3%) donors. About 87% of the respondent blood banks screen blood for hepatitis B, 95% for HIV, 94% for syphilis, 67% for malaria, and only 6% for hepatitis C. Marked heterogeneity in the test methods was observed with only 13% using ELISA kits for HBsAg. Only 21% of the blood banks prepare blood-derived components. Feedback to the blood banks on the occurrence of transfusion-associated hepatitis is given on less than 40% of occasions. CONCLUSIONS: Testing for transfusion-transmitted infections is unsatisfactory and poorly regulated in India. Reporting of adverse events after transfusion is poor and no stringent donor deferral system exists.

Blood Banks↗

Seroprevalence of hepatitis A virus antibody in patients with chronic liver disease--experience from a tertiary care hospital in north India.

Patients with chronic liver disease of any etiology are at a high risk for a more severe outcome when superinfected with hepatitis A virus (HAV). Prevention of hepatitis A, by inactivated vaccine has been shown to be safe and effective in this subgroup of patients. Most countries in the West recommend prophylaxis against hepatitis A virus for patients with chronic liver disease. However, hepatitis A virus is endemic in India. Before advocating a uniform prophylaxis against hepatitis A for chronic liver disease patients in India, we prospectively evaluated the seroprevalence of hepatitis A virus antibody (Anti HAV) among the patients with cirrhosis of liver registered at our hospital, using a commercial enzyme-immunoassay (ELISA). Prevalence of protective antibody against HAV among the 42 Cirrhotic patients included in the study was documented to be 97.6% (41/42). Therefore, vaccination against hepatitis A virus infection may not be needed among patients with chronic liver disease in our population. However, further studies including adequate sample size is needed to confirm the observation encountered in the present study.

Adult↗